Featured in Blood Health, International Myeloma Foundation Chief Medical Officer Dr. Joseph Mikhael discusses recent changes to the myeloma treatment landscape. The scope of multiple myeloma treatment is evolving rapidly, bringing new hope to patients and their loved ones. In 2024, the FDA approved two powerful four-drug combinations for newly diagnosed patients, promising deeper, longer-lasting remissions. New advancements in relapse therapies are also shifting CAR T-cell therapies and bispecific antibodies into earlier treatment lines, potentially transforming patient outcomes.

Meanwhile, research shows that lowering dexamethasone doses can maintain effectiveness while reducing harsh side effects. Plus, a new study highlights the benefits of early intervention for high-risk smoldering multiple myeloma, a potential game-changer in disease prevention.

Want to learn more about these new treatments and what they mean for myeloma care? Click the button below to read the full article!